Compare DRH & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRH | ADMA |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2004 | 2012 |
| Metric | DRH | ADMA |
|---|---|---|
| Price | $14.20 | $13.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | $14.85 | ★ $18.00 |
| AVG Volume (30 Days) | 3.1M | ★ 3.8M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 144.44 | N/A |
| EPS | ★ 0.67 | 0.57 |
| Revenue | ★ $1,120,491,000.00 | $42,219,783.00 |
| Revenue This Year | $3.32 | $4.49 |
| Revenue Next Year | $2.86 | $14.91 |
| P/E Ratio | ★ $21.18 | $23.39 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $8.60 | $7.21 |
| 52 Week High | $14.85 | $20.46 |
| Indicator | DRH | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 61.74 |
| Support Level | $13.88 | $7.84 |
| Resistance Level | $14.85 | $13.77 |
| Average True Range (ATR) | 0.35 | 0.74 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 31.96 | 74.43 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.